Barclays
OBIO icon

Barclays’s Orchestra BioMed OBIO Stock Holding History

Barclays’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.3K Sell
13,518
-45,824
-77% -$187K ﹤0.01% 4272
2026
Q1 		$252K Sell
59,342
-35,175
-37% -$150K ﹤0.01% 3555
2025
Q4 		$392K Buy
94,517
+94,516
+9,451,600% +$381K ﹤0.01% 3980
2025
Q3 		$2 Sell
1
-873
-100% -$2.41K ﹤0.01% 5437
2025
Q2 		$2.34K Sell
874
-24,735
-97% -$72.2K ﹤0.01% 5028
2025
Q1 		$110K Sell
25,609
-12,177
-32% -$60.5K ﹤0.01% 4371
2024
Q4 		$151K Buy
37,786
+6,001
+19% +$32.2K ﹤0.01% 4429
2024
Q3 		$163K Buy
31,785
+23,448
+281% +$153K ﹤0.01% 4397
2024
Q2 		$67.9K Sell
8,337
-2,111
-20% -$12.2K ﹤0.01% 4084
2024
Q1 		$55.1K Sell
10,448
-9,693
-48% -$65.7K ﹤0.01% 4598
2023
Q4 		$184K Buy
20,141
+16,988
+539% +$116K ﹤0.01% 4454
2023
Q3 		$27.5K Buy
3,153
+28
+0.9% +$188 ﹤0.01% 4086
2023
Q2 		$21.9K Sell
3,125
-3,829
-55% -$58.1K ﹤0.01% 4119
2023
Q1 		$136K Buy
+6,954
New +$80.5K ﹤0.01% 4011

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Barclays's OBIO Position: Q2 2026 in Review

Barclays reduced its Orchestra BioMed (OBIO) stake by 77% in Q2 2026, selling an estimated $187K and leaving 13,518 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4272.

Barclays first reported a position in OBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $392K in Q4 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Barclays held 13,518 shares of Orchestra BioMed worth $58.3K as of Q2 2026.
  • Barclays sold 45,824 Orchestra BioMed shares in Q2 2026, an estimated $187K.
  • Orchestra BioMed made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4272 holding.
  • Barclays first reported a position in Orchestra BioMed in Q1 2023 and has held it in 14 quarters since.
  • Barclays's Orchestra BioMed position peaked at $392K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.